US2002013270A1PendingUtilityA1

Method for treating a mental disorder

32
Priority: Jun 5, 2000Filed: May 25, 2001Published: Jan 31, 2002
Est. expiryJun 5, 2020(expired)· nominal 20-yr term from priority
Inventors:Ellen Bolte
A61P 31/04A61P 25/00A61K 35/74A61K 35/76A61K 35/745A61K 35/747A61K 31/397A61K 31/545A61P 1/00A61K 35/744A61K 35/742Y02A50/30
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating an individual exhibiting at least one symptom of a mental disorder is provided which comprises administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder. This invention also pertains to a method of treating an individual exhibiting at least one symptom of a mental disorder by administering a probiotic mixture to replenish gastrointestinal microbes. RELATED APPLICATIONS This application claims the benefits of United States Provisional Application No. 60/209,712 entitled “Method For Treating Autism” filed on Jun. 5, 2000, United States Provisional Application No. 60/214,813 entitled “Therapies for Gastrointestinal and Neurological Disorders” filed on Jun. 28, 2000, and United States Provisional Application No. 60/240,582 entitled “Method For Treating Autism—Addition 1 ” filed on Oct. 16, 2000 which are incorporated herein by reference and made a part hereof.

Claims

exact text as granted — not AI-modified
I claim:  
     
         1 . A method of treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder.  
     
     
         2 . The method of  claim 1  wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.  
     
     
         3 . The method of  claim 1  wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.  
     
     
         4 . The method of  claim 3  wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.  
     
     
         5 . The method of  claim 1  wherein the antimicrobial agent can be administered orally.  
     
     
         6 . The method of  claim 1  wherein the antimicrobial agent can be administered rectally.  
     
     
         7 . The method of  claim 1  wherein the antimicrobial agent can be administered parenterally.  
     
     
         8 . A kit for treating an individual exhibiting at least one symptom of a mental disorder, the kit comprising an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder.  
     
     
         9 . The kit of  claim 8  wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.  
     
     
         10 . The kit of  claim 8  wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.  
     
     
         11 . The kit of  claim 10  wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.  
     
     
         12 . The kit of  claim 8  wherein the antimicrobial agent can be administered orally.  
     
     
         13 . The kit of  claim 8  wherein the antimicrobial agent can be administered rectally.  
     
     
         14 . The kit of  claim 8  wherein the antimicrobial agent can be administered parenterally.  
     
     
         15 . A method of treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder and administering to the individual a probiotic mixture to replenish gastrointestinal microbes.  
     
     
         16 . The method of  claim 15  wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.  
     
     
         17 . The method of  claim 15  wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.  
     
     
         18 . The method of  claim 17  wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.  
     
     
         19 . The method of  claim 15  wherein the probiotic mixture comprises at least one gastrointestinal microbe.  
     
     
         20 . The method of  claim 19  wherein the at least one gastrointestinal microbe is selected from the group consisting of  Bifidobactrium adolescentis, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides vulgatus, Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum, Escherichia coli, Eubacterium aerofaciens, Peptostreptococcus productus , and  Streptococcus faecalis.    
     
     
         21 . The method of  claim 15  wherein the antimicrobial agent can be administered orally.  
     
     
         22 . The method of  claim 15  wherein the antimicrobial agent can be administered rectally.  
     
     
         23 . The method of  claim 15  wherein the antimicrobial agent can be administered parenterally.  
     
     
         24 . The method of  claim 15  wherein the probiotic mixture can be administered orally.  
     
     
         25 . The method of  claim 15  wherein the probiotic mixture can be administered rectally.  
     
     
         26 . A kit for treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder and administering to the individual a probiotic mixture to replenish gastrointestinal microbes.  
     
     
         27 . The kit according to  claim 26  wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.  
     
     
         28 . The kit according to  claim 26  wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.  
     
     
         29 . The kit according to  claim 28  wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.  
     
     
         30 . The kit according to  claim 26  wherein the probiotic mixture comprises at least one gastrointestinal microbe.  
     
     
         31 . The kit according to  claim 30  wherein the at least one gastrointestinal microbe is selected from the group consisting of  Bifidobactrium adolescentis, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides vulgatus, Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum, Escherichia coli, Eubacterium aerofaciens, Peptostreptococcus productus , and  Streptococcus faecalis.    
     
     
         32 . The kit according to  claim 26  wherein the antimicrobial agent can be administered orally.  
     
     
         33 . The kit according to  claim 26  wherein the antimicrobial agent can be administered rectally.  
     
     
         34 . The kit according to  claim 26  wherein the antimicrobial agent can be administered parenterally.  
     
     
         35 . The kit according to  claim 26  wherein the probiotic mixture can be administered orally.  
     
     
         36 . The kit according to  claim 26  wherein the probiotic mixture can be administered rectally.

Join the waitlist — get patent alerts

Track US2002013270A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.